Mutation Hikes Death Risk in Thyroid Cancer (CME/CE)

(MedPage Today) -- Patients with papillary thyroid cancer (PTC) who are carriers of the BRAF V600E mutation had worse mortality, researchers found.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news

Related Links:

In conclusion, we found elevated levels of circulating FGF-23 with hypercalcemia following the discontinuation of denosumab. FGF-23 might be a surrogate marker for massive bone resorption triggered by discontinuation of long-term denosumab treatment. PMID: 31527321 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
Conclusions: In MTC patients with increased Ctn and no known distant metastases, F-18-Dopa PET/CT is more sensitive to detect structural disease than any other imaging modality, including WB MRI. PMID: 31530235 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
CONCLUSION: Expression of a constitutively activated ALK mutant in thyroids of mice leads to development of metastasizing thyroid cancer resembling human PDTC. These results demonstrate in vivo that increased ALK activity is a driver mechanism in thyroid carcinogenesis. PMID: 31526103 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Authors: Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R Abstract To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial c...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Rebecca Hetherington, now 29, from Newcastle, started to feel unwell in 2013. She was diagnosed with stage two metastatic papillary thyroid cancer on May 17 2016 after a locum GP referred her for a scan.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conclusion: The proposed newly devised hypothyroid scale correctly identified subjects with TSH elevation and clinical/subclinical hypothyroidism based on their clinical signs and symptoms. In this particular subset of patients, the hypothyroid symptom scale showed a statistically significant improvement in the sum of the signs and symptoms with the normalization of the subjects' thyroid function.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Publication date: October 2019Source: Canadian Journal of Diabetes, Volume 43, Issue 7, SupplementAuthor(s): Kirstie Lithgow, Helen Huang, Denise Chan, Moosa Khalil, Mike Bristow, Vincent Dinculescu, Markus Eszlinger, Vicky Parkins, Ralf Paschke
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
This study aims to analyze complication rates of thyroid surgery, papillary thyroid microcarcinoma recurrence, and survival rates. Additionally, the costs of surgery versus hypothetic active surveillance for papillary thyroid microcarcinoma are compared in an Australian cohort.
Source: Surgery - Category: Surgery Authors: Source Type: research
Background: Analysis of plasma circulating cell-free DNA integrity (cfDI) has emerged as a promising tool in the diagnosis of malignant vs. benign tumors. There is limited data on the role of cfDI in thyroid cancer. The goal of this study was to analyze cfDI as a biomarker of malignancy in patients with cytologically indeterminate thyroid nodules.Methods: The cfDI was measured in the plasma of patients with cytologically indeterminate thyroid nodules. All patients underwent plasma collection within 24–72 h before surgical treatment for thyroid nodules. Additionally, samples were collected from seven patients via the ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Thyroid | Thyroid Cancer